Bio-Techne Corporation (TECH)
Nasdaq · Healthcare · Biotechnology
$72.58+0.25%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $11.4B
- P/E (trailing)
- 62.6
- Forward P/E
- 31.4
- Dividend yield
- 0.4%
- 52-week range
- $43.20 – $72.69
- 52-week change
- +22.32%
- EPS (trailing)
- $1.16
- Analyst rating
- 2.8 Hold
- Next earnings
- Nov 9, 2026
Fiscal year to Jun 2026
- Revenue
- $1.2B (−0.38%)
- Operating margin
- 20.7%
- Diluted EPS
- $1.16
- Free cash flow
- $263M
From the company’s annual report on SEC EDGAR.
About Bio-Techne Corporation
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids.
Headquarters: Minneapolis, United States · 3,000 employees · bio-techne.com